Cronos Group Inc vs Samsara Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Samsara Inc trades at $41.5 (market cap $24.14B). The key difference: Samsara Inc is far larger — about 20.5× Cronos Group Inc's market cap, and Cronos Group Inc is more actively traded (968,037 versus 5,372,580). Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Samsara Inc for 19 Days on average.
| CRON | IOT | |
|---|---|---|
Market Cap | $1.18B | $24.14B |
Volume | 968,037 | 5,372,580 |
Sector | Health | Technology |
52-Week High | $3.55 | $45.22 |
52-Week Low | $2.30 | $24.25 |
Typical Hold Time | 22 Days | 19 Days |
Enterprise Value | $387.62M | $23.38B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
Samsara Inc. (IOT) trades at $40.51, down 2.95% on the day, yet maintains a bullish technical trend with strong analyst support. The company reported robust Q2 2027 results, beating EPS estimates with $0.20 versus $0.16 expected, and achieved 30% year-over-year revenue growth. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion. The stock is supported by a consensus price target of $51.15, indicating significant upside potential from current levels.
The outlook for IOT is positive, driven by strong earnings momentum and large-customer adoption, though high valuation multiples (P/E 274.8, P/S 13.01) pose a risk if growth slows. Investors face execution risks amid competitive pressures, but institutional accumulation and a 75% buy rating from analysts suggest confidence in sustained growth. Key catalysts include continued revenue expansion and margin improvement, while monitoring cash flow trends remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →